Immune‐related signature predicts the prognosis and immunotherapy benefit in bladder cancer-Reference-Cited by-同舟云学术

Immune‐related signature predicts the prognosis and immunotherapy benefit in bladder cancer

Published:2020-08-25 Issue:20 Volume:9 Page:7729-7741
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Wang Yejinpeng¹,Chen Liang¹^ORCID,Yu Mengxue²³⁴,Fang Yayun²³⁴,Qian Kaiyu²³⁴,Wang Gang²³⁴^ORCID,Ju Lingao²³⁴^ORCID,Xiao Yu¹²³⁴⁵^ORCID,Wang Xinghuan¹⁶^ORCID

Affiliation:

1. Department of Urology Zhongnan Hospital of Wuhan University Wuhan China

2. Department of Biological Repositories Zhongnan Hospital of Wuhan University Wuhan China

3. Human Genetics Resource Preservation Center of Hubei Province Wuhan China

4. Human Genetics Resource Preservation Center of Wuhan University Wuhan China

5. Laboratory of Precision Medicine Zhongnan Hospital of Wuhan University Wuhan China

6. Medical Research Institute Wuhan University Wuhan China

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.3400

Reference51 articles.

1. Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends

2. The mechanism of action of BCG therapy for bladder cancer—a current perspective

3. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

4. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial

5. The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Glutathione S‐transferase omega class 1 (GSTO1)‐associated large extracellular vesicles are involved in tumor‐associated macrophage‐mediated cisplatin resistance in bladder cancer;Molecular Oncology;2024-05-15

2. Preliminary findings on the development of a predictive model for BLCA based on disulfidptosis-associated IncRNAs signature;BMC Urology;2024-03-26

3. Immunotherapy: The Fourth Domain in Oral Cancer Therapeutics;Indian Journal of Otolaryngology and Head & Neck Surgery;2024-03-10

4. Synergistic role of activated CD4+ memory T cells and CXCL13 in augmenting cancer immunotherapy efficacy;Heliyon;2024-03

5. Novel Therapeutic Targets and Biomarkers Associated with Bladder Cancer‐Associated Fibroblasts (CAFs) Promoted by Bisphenol A;Journal of Clinical Pharmacy and Therapeutics;2024-01